MA-BRIGHTCOVE/WIBBITZ
13.7.2021 15:02:14 CEST | Business Wire | Press release
Media professionals, marketers, and corporate communicators can now rapidly expand their catalogs of business video with a new, tightly knit integration of the Wibbitz video creation tool and Brightcove ® (NASDAQ: BCOV), the global leader in video for business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005375/en/
With smart automation driving Wibbitz video creation, the combination of Brightcove and Wibbitz is one of the easiest and most effective ways for companies to quickly create professional quality short-form videos that engage viewers, nurture sales leads through to closure, and provide valuable information to shareholders, customers, and employees.
Creators, even those with no experience, can now access Wibbitz from their Brightcove Video Cloud interface and intuitively create polished videos from scratch. Wibbitz provides templates and rights-cleared photos and music tracks, animations, transitions, video clips, and other media. Users can then distribute the newly created videos through the Brightcove platform to any person on any device and on any channel, anywhere in the world. The integration also makes it easy to use Wibbitz to refresh videos stored in a Brightcove library with new content or effects before redistribution.
“As a long-time Wibbitz user, I’m excited about the integration with Brightcove and the ability to easily bring more scale, security, and reliability to our video content,” said Marco Viganò, Chief Technology Officer, Condé Nast Italy. “We believe video is the most powerful communications tool to engage our audiences. To us, the Wibbitz and Brightcove combination is now a single, seamless experience of video creation, distribution, and optimization.”
“Creators use Wibbitz to tell their stories with video, and they need the most reliable, comprehensive, and effective solution to make sure those stories reach their audience. Brightcove hits the mark,” said Zohar Dayan, Chief Executive Officer, Wibbitz. “This partnership simplifies video workflows to make each step easier, from production to publishing and analytics, so media companies and enterprises can focus on sharing stories that drive real impact.”
“Although Brightcove can easily manage, play, and measure any video created in any tool, we want to help make creators’ lives easier,” said Namita Dhallan, Chief Product Officer, Brightcove. “That means lowering the barrier to creation, especially for organizations that want to quickly and easily build up video volume and execute new video strategies themselves. Wibbitz is a great way to do that.”
Wibbitz and Brightcove exchange all relevant data, including authentication via single sign-on, user profile information, and available video files. Wibbitz also helps organizations ensure that every video is on brand with the right logos, watermarks, custom fonts, and color palettes.
To try Wibbitz for free, visit here .
About Wibbitz
Wibbitz is a video creation company that empowers content teams to produce professional short-form video. The Wibbitz online platform makes it quick and easy to create video for social media, news & entertainment coverage, marketing, communications, recruitment, events, and more. Creators have access to customizable video templates, drag-and-drop editing tools, a team of in-house experts, and millions of licensed photos, videos, and soundtracks. Wibbitz powers video for leading brands including HubSpot, Bloomberg, Condé Nast, S&P Global, Bain & Company, BP, and more. Wibbitz was founded in 2011 and has offices in New York City, Tel Aviv, and Paris. For more information, visit www.wibbitz.com and follow @wibbitz .
About Brightcove Inc.
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom